Currie G P, Lipworth B J
From the Consultant Chest Physician, Chest Clinic C, Aberdeen Royal Infirmary, Aberdeen, UK
Consultant Chest Physician, Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, Dundee, UK.
QJM. 2016 Aug;109(8):505-12. doi: 10.1093/qjmed/hcv212. Epub 2015 Nov 11.
Since chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow obstruction, inhaled bronchodilators form the mainstay of treatment. A variety of new inhaled drugs and inhaler devices have recently been licensed and approved for prescribing to patients with COPD; many such drugs have been formulated in devices to deliver two different drugs at the same time. The evidence based review article highlights all of the drugs now licensed, describes some of the evidence surrounding their use and highlights practical steps in helping decide when these drugs should be considered in the context of guidelines.
由于慢性阻塞性肺疾病（COPD）的特征是进行性气流受限，吸入性支气管扩张剂构成了治疗的主要手段。最近，多种新型吸入药物和吸入装置已获得许可并被批准用于COPD患者的处方；许多此类药物已被制成能同时递送两种不同药物的装置。这篇循证综述文章重点介绍了目前已获许可的所有药物，描述了围绕其使用的一些证据，并强调了在指南背景下帮助决定何时应考虑使用这些药物的实际步骤。
